Another one bites the dust: Bristol Myers Squibb pulls 'dangling' accelerated approval for Opdivo in liver cancer

Bristol Myers Squibb has agreed to pull a second-line liver cancer indication for its blockbuster Opdivo as a monotherapy, becoming the second PD-(L)1 indication to bite the dust after the FDA’s oncology adcomm reviewed six “dangling” accelerated approvals in April.